Greenyn Biotechnology Co., Ltd
6846
Rank in Stocks
#23879
Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary... Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary supplements, dedicated to the development, production, and worldwide distribution of health-enhancing products. Their product portfolio includes a range of proprietary active ingredients. These feature notable components such as Insumate, derived from bitter melon extract; Antromax, which utilizes antrodia cinnamomea; and the Zymologist 101 Phyto fermented drink. Beyond individual ingredients, Greenyn provides an extensive selection of functional product series catering to a diverse array of health and wellness needs. These encompass solutions for youth and beauty, digestive and brain health, overall body regulation, throat care, hair care, vision support, and various lifestyle enhancement formulas. Additional ranges include joint health, general nutritional and energy supplementation, immune modulation, low-burden options, sleep assistance, body contouring, circulatory support, specific formulas for men's vitality and women's intimate health, and dedicated products for mature women. Moreover, the company extends its expertise through various services, including custom product development, Original Design Manufacturing (ODM), dosage form optimization, and application support. Established in 2012, the firm's operations are headquartered in Taichung, Taiwan.
Share Price
$1.40
Last synced: 2026-11-10
Market Cap
$37.91M
Change (1 day)
-9.01%
Change (1 year)
-42.65%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Greenyn Biotechnology Co., Ltd (6846)
Category
Healthcare
Operating Margin for Greenyn Biotechnology Co., Ltd (6846)
Operating Margin as of November 2026 TTM: 18.19%
According to Greenyn Biotechnology Co., Ltd's latest financial reports, its current operating margin (TTM) is 18.19%. At the end of 2025 the company had an operating margin of 20.61%.
Operating Margin history for Greenyn Biotechnology Co., Ltd from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 18.19% | -11.74% |
| 2025 | 20.61% | 7.23% |
| 2024 | 19.22% | -3.71% |
| 2023 | 19.96% | -24.02% |
| 2022 | 26.27% | 6.96% |
| 2021 | 24.56% | 1.91% |
| 2020 | 24.10% | 8.56% |
| 2019 | 22.20% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -97.88% |
US
|
|
| -149.01% | -108.19% |
US
|
|
| 25.57% | -98.59% |
AU
|
|
| 31.23% | -98.28% |
BE
|
|
| 29.35% | -98.39% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Greenyn Biotechnology Co., Ltd's operating margin
What is Greenyn Biotechnology Co., Ltd's operating margin?
Greenyn Biotechnology Co., Ltd's operating margin is 18.19%, as of Nov 2026.
What was Greenyn Biotechnology Co., Ltd's operating margin in 2025?
In 2025, Greenyn Biotechnology Co., Ltd's operating margin was 20.61%, compared with 19.22% in 2024.
How has Greenyn Biotechnology Co., Ltd's operating margin changed since 2020?
From 2020 to 2025, Greenyn Biotechnology Co., Ltd's operating margin was highest in 2022 (26.27%) and lowest in 2024 (19.22%).
How does Greenyn Biotechnology Co., Ltd's operating margin compare with similar companies?
Greenyn Biotechnology Co., Ltd's operating margin (18.19%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.